Chronic administration of PDTC to ZDF rats restored AT1 receptor function and expression, and reduced renal inflammation and oxidative stress, suggesting that inhibition of NF-κB activation may be effective adjuncts to the current treatment of hypertension, although studies of safety and toxicity are required before such drugs can be considered for clinical use. This evidence concerns the gene AGTR1 and hypertensive disorder.